Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Pekáriková A, Sánchez D, Palová-Jelínková L, Simsová M, Benes Z, Hoffmanová I, Drastich P, Janatková I, Mothes T, Tlaskalová-Hogenová H, Tucková L.

Clin Exp Immunol. 2010 May;160(2):215-22. doi: 10.1111/j.1365-2249.2009.04085.x. Epub 2009 Dec 17.

2.

Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.

Sánchez D, Palová-Jelínková L, Felsberg J, Simsová M, Pekáriková A, Pecharová B, Swoboda I, Mothes T, Mulder CJ, Benes Z, Tlaskalová-Hogenová H, Tucková L.

Clin Exp Immunol. 2008 Sep;153(3):351-9. doi: 10.1111/j.1365-2249.2008.03701.x. Epub 2008 Jul 11.

3.

Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector.

Connell TG, Shey MS, Seldon R, Rangaka MX, van Cutsem G, Simsova M, Marcekova Z, Sebo P, Curtis N, Diwakar L, Meintjes GA, Leclerc C, Wilkinson RJ, Wilkinson KA.

Clin Vaccine Immunol. 2007 Jul;14(7):847-54. Epub 2007 May 23.

4.

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C, Brodin P, Sebo P, Leclerc C.

Infect Immun. 2006 Jun;74(6):3396-407.

6.

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Majlessi L, Simsova M, Jarvis Z, Brodin P, Rojas MJ, Bauche C, Nouzé C, Ladant D, Cole ST, Sebo P, Leclerc C.

Infect Immun. 2006 Apr;74(4):2128-37.

7.

Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing.

Anderson ST, Williams AJ, Brown JR, Newton SM, Simsova M, Nicol MP, Sebo P, Levin M, Wilkinson RJ, Wilkinson KA.

Am J Respir Crit Care Med. 2006 May 1;173(9):1038-42. Epub 2006 Feb 2.

PMID:
16456140
8.

Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara.

Mackova J, Stasikova J, Kutinova L, Masin J, Hainz P, Simsova M, Gabriel P, Sebo P, Nemeckova S.

Cancer Immunol Immunother. 2006 Jan;55(1):39-46. Epub 2005 Oct 27.

PMID:
15926077
9.

Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids.

Wilkinson KA, Simsova M, Schölvinck E, Sebo P, Leclerc C, Vordermeier HM, Dickson SJ, Brown JR, Davidson RN, Pasvol G, Levin M, Wilkinson RJ.

Infect Immun. 2005 May;73(5):2991-8.

10.

[Treatment of the Hirschsprung's disease (HD) at the Department of Pediatric Surgery of Charles University, 2nd Faculty of Medicine, from 1979 to 2004].

Skába R, Rousková B, Simsová M, Kalousová J, Pýcha K.

Cas Lek Cesk. 2004;143(11):748-51. Czech.

PMID:
15628569
11.

Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis.

Vordermeier HM, Simsova M, Wilkinson KA, Wilkinson RJ, Hewinson RG, Sebo P, Leclerc C.

Infect Immun. 2004 Nov;72(11):6255-61.

12.

The adenylate cyclase toxin from Bordetella pertussis--a novel promising vehicle for antigen delivery to dendritic cells.

Simsova M, Sebo P, Leclerc C.

Int J Med Microbiol. 2004 Apr;293(7-8):571-6. Review.

PMID:
15149033
13.

[Transanal resection of the recto-sigmoid--the future in the treatment of classic Hirschsprung's disease?].

Skába R, Kalousová J, Simsová M, Rousková B, Frantlová M, Mixa V.

Rozhl Chir. 2003 Dec;82(12):620-3. Czech.

PMID:
14746230

Supplemental Content

Loading ...
Support Center